Msh3-/- SVG-A Cell Line

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Msh3-/- SVG-A Cell Line
• Alternate name: DNA mismatch repair protein Msh3, hMSH3, Divergent upstream protein, DUP, Mismatch repair protein 1, MRP1
• Research fields: Cancer;Cell biology;Genetics
• Tool sub type: Continuous
• Parental cell: SVG-A immortalized human astrocytes
• Organism: Human
• Tissue: Brain
• Disease: Neurodegenerative diseases
• Growth properties: Adherent cell line
• Model: Knock-Out
• Conditional: No
• Description: The MSH3 gene encodes a DNA mismatch repair protein important in certain cancer types and in certain neurodegenerative diseases.Exon 2 of the MSH3 gene was targeted by CRISPR/Cas9. The resulting Msh3-/- cell line encodes a 3 amino acid deletion in Msh3 that results in 98% loss of Msh3 protein, as judged by western blots with two different antibodies.While ~98% of Msh3 protein is lost in these cells, the abundance of the related proteins Msh2 and Msh6 appear unaffected. This is relevant to DNA mismatch repair.
• Application: Applications tested: DNA repair assays Microsatellite instability Trinucleotide expansion assay Cell background for rescue with wild type or variant Msh3 clones Immunoprecipitation control for Msh2-Msh3 protein complex Functional analysis of Msh3 variants
• Production details: Exon 2 of the MSH3 gene was targeted by CRISPR/Cas9. The resulting Msh3-/- cell line encodes a 3 amino acid deletion in Msh3 that results in 98% loss of Msh3 protein, as judged by western blots with two different antibodies.
• Biosafety level: 1
• Additional notes: CRISPR edited cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide the...
• Recommended controls: SVG-A Cell Line, SVG-A Msh3 1.7X Cell Line (derived from Msh3-/- SVG-A Cell Line)

Target Details

• Target: Msh3

Applications

• Application: Applications tested: DNA repair assays Microsatellite instability Trinucleotide expansion assay Cell background for rescue with wild type or variant Msh3 clones Immunoprecipitation control for Msh2-Msh3 protein complex Functional analysis of Msh3 variants
• Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

Handling

• Format: Frozen
• Growth medium: DMEM supplemented with 10% FBS
• Unit size: 1x10^6 cells / vial
• Shipping conditions: Dry ice
• Storage conditions: Liquid Nitrogen
• Mycoplasma free: Yes

Related Tools

• Related tools: SVG-A Cell Line ; SVG-A Msh3 1.7X Cell Line

References

• Keogh et al. 2017. Nucleic Acids Res. 45(17):10068-10078. PMID: 28973443.
• MutS? abundance and Msh3 ATP hydrolysis activity are important drivers of CTGCAG repeat expansions.